China-based Jiaxing Pharbers Genesis has reportedly raised RMB 100 million (USD 13.74 million) in a Series A2 financing round. The round was led by the Beijing Isotope and Radiation Innovative Industry Investment Fund, which was initiated by China National Nuclear Corporation (CNNC) and China Isotope and Radiation Corporation, with participation from the National Military-Civilian Integration Fund and Beijing local government.
Investment to Accelerate Pipeline R&D and Plant Construction
The proceeds from this financing round will be directed towards the research and development of Faber Xintian Pharma’s pipeline and the construction of a radiopharmaceuticals plant. This strategic investment is expected to strengthen the company’s position in the radiopharmaceuticals sector and enhance its capabilities in developing innovative treatments.
Support from Key Industry and Government Entities
The support from leading industry players and government entities underscores the significance of Faber Xintian Pharma’s work in the field of radiopharmaceuticals. The investment not only provides the necessary capital for expansion but also validates the company’s potential to contribute to the advancement of nuclear medicine and related therapies.-Fineline Info & Tech
